Posted by Michael Wonder on 09 Feb 2021
ShiraTronics receives FDA breakthrough device designation for chronic migraine neurostimulation
8 February 2021 - ShiraTronics announced today that it has been granted a breakthrough device designation by the Center of Devices and Radiological Health of the FDA for its innovative neurostimulation therapy targeting the millions of chronic migraine sufferers.
ShiraTronics was created to be the world's leading provider of innovative therapy for migraine headaches.
